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The hepatitis C virus (HCV) subgenomic replicon system was used to study a possible involvement of nonstructural protein 5A (NS5A) in the
mechanisms ofHCVresistance to interferon alpha (IFN-a). A series of chimericHCVrepliconswas constructed. In these replicons, theNS5Agene
in the backbone of theCon1 repliconwas swapped by corresponding fragments obtained from four IFN-a responder and four IFN-a nonresponder
patients that had been infected with the same HCVAD78 strain. Experiments with transfected Huh7 cells did not reveal significant differences in
sensitivity of HCV RNA replication to IFN-a in cell clones, bearing chimeric Con1/AD78 replicons with NS5A sequences from IFN responders
and nonresponders. Thus, these data provide no evidence that the NS5A protein contributes to the resistance of HCV replication to IFN-a.
D 2005 Elsevier Inc. All rights reserved.Keywords: HCV; NS5A; IFN-aIntroduction
The most intriguing avenues of HCV research are the
mechanisms and the role of HCVresistance to interferon. The
establishment of HCV acute infection is associated with the
production of interferons as part of the innate immune
response. It is assumed that the induced interferons may
inhibit HCV replication in a direct nonspecific fashion and
trigger a series of events that lead to the development of
specific antiviral immune responses. The ability of a
particular virus strain to circumvent some of the antiviral
effects of interferons might cause a change in the outcome of
the infection. Analysis of the HCV resistance to interferon is
very important for medical virology. Nowadays, the com-
bined therapy with interferon alpha (IFN-a) and ribavirin
remains the only available option for treatment of patients0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.03.012
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E-mail address: sergei.viazov@uni-essen.de (S. Viazov).with chronic hepatitis C. Unfortunately, many patients,
especially those infected with HCV type 1 strains, often
demonstrate no sustained virological and biochemical
response to therapy (Pawlotsky and Germanidis, 1999). The
mechanisms of such a resistance are still unclear; however,
the involvement of both host and viral factors is considered
(Gao et al., 2004; Pavio and Lai, 2003). A failure to achieve a
sustained virological response after therapy might be
associated with the inability of interferon to trigger adequate
immune responses in individuals with a particular genetic
background or in patients in a particular physiological state.
Thus, recently published data suggest that therapy-induced
viral clearance and maintenance of a nonviremic state may be
associated with the induction, expansion, and circulation of
HCV antigen-specific cytolytic T cells (Morishima et al.,
2003). Varied response rates to interferon–ribavirin therapy
in patients infected with different genotypes suggest that viral
factors might also influence the outcome of the treatment.
During the last decade, a series of publications on the possible
involvement of HCV proteins and, in particular, of the viral05) 131 – 136
Rapid Communication132nonstructural protein NS5A in the mechanisms of resistance
to interferon therapy were presented (Enomoto et al., 1995;
He and Katze, 2002; Pawlotsky and Germanidis, 1999).
Although conflicting clinical data on the relevance of NS5A
were reported (He and Katze, 2002; Macdonald and Harris,
2004; Pawlotsky and Germanidis, 1999), recently, a meta-
analysis confirmed a correlation between the NS5A sequence
and IFN response (Schinkel et al., 2004). Series of in vitro
experiments with different types of cells, overexpressing
NS5A protein, also provided somewhat contradictory results
and might have not completely modeled the situation
occurring in natural infection of human hepatocytes (He
and Katze, 2002; Macdonald and Harris, 2004). A possibility
to study the role of NS5A under ‘‘more physiological
conditions’’ appeared after development of the HCV sub-
genomic replicon model (Blight et al., 2000; Lohmann et al.,
1999). Several laboratories demonstrated that replication of
HCVreplicons in Huh7 cells was sensitive to exogenous IFN-
a (Blight et al., 2000; Frese et al., 2001; Guo et al., 2001), and
the observed effects seemed to be independent of the type of
NS5A. These results did not confirm previous clinical and
laboratory observations, thus adding some more confusion.
The current report describes a series of experiments
directed at the analysis of the sensitivity to IFN-a of a
number of chimeric replicons, in which the NS5A gene in
the backbone of the Con1 replicon was swapped by
corresponding fragments obtained from IFN-a responder
and nonresponder patients. The important peculiarity of this
approach is that all these sequences were obtained from
patients infected with the same HCVAD78 strain in a single
source outbreak of hepatitis C caused by contaminated anti-
D globulin (Dittmann et al., 1991; Wiese et al., 2000). This
unique approach allowed to eliminate an additional intrinsic
uncertainty that arises if NS5A fragments from patients
infected with different HCV strains are used.Results
DNA fragments corresponding to the NS5A region were
amplified from sera of eight patients chronically infected
with the same HCV isolate AD78. Four of these patients did
not respond to IFN-a treatment, the other four patients
demonstrated a sustained virological and biochemical
response. The amplified DNA fragments were subjected to
direct sequencing and the resulting deduced amino acid
sequences, corresponding to the predominant virus type,
were aligned with the sequence of the corresponding
fragment from Con1 HCV isolate. Fig. 1 demonstrates that
the sequences of eight HCVAD78-derived isolates, includ-
ing four isolates obtained from the IFN nonresponders (NR
1–4) and four isolates obtained from IFN responders (R 1–
4) differed from the Con1 sequence in at least 21 amino acid
positions. Most of these substitutions, however, did not
occur within the interferon sensitivity determining region
(ISDR). Analysis of the amino acid variation of eight AD78-derived sequences did not reveal a particular mutation or a
motif, associated with the lack of response to IFN-a therapy.
The amplified NS5A fragments from eight AD78 isolates
were additionally cloned and sequenced, and the clones
containing the predominant variants of sequences (Fig. 1)
were used for the construction of a series of hybrid Con1/
AD78 subgenomic replicons, in which the original NS5A
sequence of Con1-based replicon (Lohmann et al., 1999)
was swapped by corresponding fragments of HCV AD78
isolates obtained from four IFN responders and four
nonresponders (Fig. 2). The RNAs, transcribed in vitro
from the prepared chimeric constructs, were used for
transfection of Huh7 cells with a subsequent selection of
G418-resistant cells. With the hybrid Con1/AD78 constructs
we were able to establish G418-resistant cell lines. Three of
them harbored the chimeric replicons, containing the NS5A
sequences (R1 to R3) from three IFN-a responder patients,
and the other three cell lines beared the replicons, containing
the NS5A sequences (NR1 to NR3) from the IFN-a
nonresponder patients. Multiple attempts to transfect cells
with constructs bearing the NS5A region from patients R4
and NR4 were unsuccessful. The Northern blot analysis of
the total RNA from the established six cell lines demon-
strated the presence of subgenomic HCV RNA molecules
(Fig. 3). Expression of NS5A protein in these cells was
confirmed by Western blot (data not shown). Quantification
of the HCV RNA in these cell clones revealed a slight
variability of the replicon copy number from 2.0  106 to
1.5  107 RNA copies per microgram of total RNA at
different cell passages. Direct sequencing of the amplified
viral sequences from the six cell lines has demonstrated that
the predominant NS5A sequences of all chimeric replicons
remained stable and no conserved changes from the original
predominant sequences (Fig. 1) occurred over a 5-month
culture period of the current study.
The established lines of Huh7 cells bearing the six
chimeric replicons were used to assess the sensitivity of
HCV replication to interferon. The transfected cells were
treated with different concentrations of IFN-a. After 48 h of
incubation, total cell RNA was extracted and the number of
replicon molecules was determined by a quantitative real-
time RT-PCR (Figs. 4A and 4B). Dose-dependent inhibition
of HCV replication was observed and a 50% inhibitory
concentration (IC50) for each of six clones was determined
(Fig. 4C). Repetitive experiments did not reveal significant
differences in sensitivity of HCV RNA replication to
interferon neither between cell clones, bearing replicons
with NS5A sequences from IFN responders and non-
responders, nor between these clones and control cells
bearing the original Con1-based replicon.Discussion
The aim of the current study was to investigate a
possible contribution of the NS5A region to the HCV
Fig. 1. Alignment of amino acid sequences of NS5A and a fragment of NS5B (positions 1973–2430, Con1 isolate, GenBank accession no. AJ238799) of the
Con1-based replicon (plasmid pFK-I389/NS3-3V/ET; Lohmann et al., 2003) and of eight HCVAD78-derived isolates, including four isolates obtained from the
IFN nonresponders (NR 1–4) and four isolates obtained from IFN responders (R 1–4). Positions of the restricted fragments used for cloning are indicated by
arrows. ISDR is underlined.
Rapid Communication 133replication resistance to interferon. The methodical
approach used for this purpose provided several advan-
tages. First, the use of a HCV subgenomic replicon system
allows to study the role of NS5A in context of other HCV
proteins, which is of special importance as many HCV
proteins, including NS5A, are known to function predom-
inantly in complex with each other within the host cell
(Appel et al., 2005; Penin et al., 2004). Second, the NS5A
fragments were inserted into the backbone of Con1
replicon that had already been adapted for replication in
Huh7 cells (Lohmann et al., 2003). We assumed that such
a replicon would tolerate the insertion of at least severalnative variants of NS5A. Indeed, the validity of this
approach was demonstrated by the fact that we were able
to obtain replication-competent replicons with six of eight
constructs tested. Third, in our approach, the HCV Con1
replicon was used as a backbone for swapping the NS5A
fragment from HCV isolates, which were obtained from
IFN-a therapy responder and nonresponder patients
infected with the same HCV AD78 strain in a single
source outbreak (Dittmann et al., 1991; Wiese et al., 2000).
The patients were infected with the same contaminated
material, or in other words, with the same quasispecies.
Treatment of the HCV AD78-infected patients with
Fig. 2. Construction of hybrid HCV subgenomic replicons. A schematic presentation of the HCV genome organization is given at the top. The structure of the
selectable HCV replicon and the inserted fragments of NS5A are shown below. The original NS5A sequence of the Con1-based replicon (plasmid pFK-I389/
NS3-3V/ET; Lohmann et al., 2003) was swapped by corresponding fragments from HCV AD78 isolates obtained from IFN responders and nonresponders.
Arrows indicate the position of the restriction sites used for insertion of NS5A fragments into the original pFK-I389/NS3-3V/ET plasmid.
Rapid Communication134interferon led to different outcomes, including the lack of a
sustained virological response, suggesting appearance of
IFN-resistant virus variants in some patients. Thus, use of
HCV isolates from IFN responder and nonresponder
AD78-infected patients provided a unique opportunity to
study and compare the sensitivity to interferon of HCV
replicon molecules in which NS5A fragments from related
but not identical variants of the same virus strain were
used. Finally, one might have expected that the propaga-
tion of the cells, bearing the chimeric HCV subgenomic
molecules, would lead to appearance of adaptive mutations
in the NS5A. Such mutations could influence the
sensitivity of these replicons to interferon. Fortunately,
the NS5A sequence of all these six replicons was
unchanged and identical to the original predominant
sequences of natural HCV isolates, and remained stable
for the whole period of our series of experiments (about 5
months). In this respect, our chimeric constructs behaved
like a recently described Con1-derived subgenomic repli-
con K2040, which remained stable and unchanged over a
16-month period of cultivation in Huh7 cells (Sumpter etFig. 3. Northern blot analysis of HCV replicon RNAs in Huh7 cells
bearing chimeric Con1/AD78 replicons. 109, 108, and 107 are the serial
dilutions of in vitro RNA transcripts. NC: negative control, RNA from
naive Huh7 cells. PC: positive control, RNA from Huh7 cells bearing the
original Con1 replicon. R1 to R3 and NR1 to NR3: RNAs from the G418-
resistant Huh7 cell lines bearing the chimeric replicons, containing the
NS5A sequences from IFN responders (R) and IFN nonresponders (NR),
correspondingly. Beta-actin RNA served as a control to correct for the
amount of total RNA.al., 2004). Using this experimental approach, we tried to
find a difference in response to IFN-a among the six of
chimeric Con1/AD78 replicons. No such difference was
registered however between replicons containing NS5A
fragments of viral isolates obtained from IFN therapy
responders and nonresponders. Even more so, all replicons
tested, including the original Con1 molecule, demonstrated
very similar sensitivity to IFN-a (Fig. 4). Thus, our data
provide no evidence that the NS5A protein influences the
resistance of HCV replication to IFN-a in vitro. It is
important to note that we have no proof that the four virus
isolates obtained from IFN nonresponder patients were true
IFN-resistant variants, which were present in the original
quasispecies population or appeared upon a selective
pressure by interferon within the context of the individual
infection. One cannot exclude that the absence of a
therapeutic effect of IFN-a in these four patients was
determined by host factors, which remain undefined. Thus,
the data of the current study suggest that a lack of a
sustained virological response to IFN-a therapy in these
four patients might have been due to host rather than viral
factors or that NS5A is not the major viral determinant of
nonresponsiveness to IFN-a.
Despite these results, we believe that the efforts directed
at the establishment of the role of NS5A in the resistance of
HCV to interferon should be continued. Thus, we cannot
exclude that Huh7 cells due to their specific characteristics
do not provide the adequate biochemical environment for
realization of all biological potentials of HCV gene
products. From this point of view, it would be logical to
extend the current study and to use cell lines other than
Huh7 to analyze the sensitivity to interferon of HCV
replicons, bearing different variants of NS5A. Finally, it
was already suggested that the modulating activity of NS5A
is associated with the ability of this protein to induce some
factors, e.g., interleukin 8 (Polyak et al., 2001), which
display their ‘‘anti-interferon’’ activity directly or indirectly
at the level of the organism. If the last suggestion is true,
then the mechanisms of resistance of HCV to interferon
Fig. 4. Inhibitory effect of IFN-a on HCV RNA levels in cells bearing the chimeric Con1/AD78 replicons. Huh7 cells transfected with Con1 replicon (positive
control, PC) or hybrid Con1/AD78 constructs, containing NS5A sequences of IFN-responding (A) and -nonresponding (B) patient isolates, were treated with 0,
0.55, 1.67, 5, 15, 45, and 135 U/ml IFN-a for 48 h and assayed for the replicon copy numbers by quantitative RT-PCR. The HCV RNA levels of untreated
control cells were compared with those found in cells treated with IFN-a, and the percentage of remaining RNAwas plotted against the IFN-a concentrations.
The bars represent the standard deviation of triplicate experiments. (C) 50% inhibitory concentrations (IC50) of IFN-a for chimeric Con1/AD78 replicons and
for the original Con1 replicon (mean T SD).
Rapid Communication 135would be elucidated only after an adequate small animal
model for HCV became available.Materials and methods
DNA amplification and plasmid construction
Serum samples from eight patients chronically infected
with HCV AD78 strain in a single source outbreak (four
interferon responders and four nonresponders) (Lu et al.,
1999; Wiese et al., 2000) were used for RNA isolation.
Serum samples from four responders were obtained 1–3
months before the start of the therapy and samples from four
nonresponder patients were obtained 12–16 months after
the initiation of the therapeutic intervention. The extracted
RNA was reverse transcribed using primer SV63 (5V-
GCGTCCAACCAGAGAAGGG) and Thermoscript reverse
transcriptase (Invitrogen). DNA fragments were subse-
quently amplified by nested PCR with primer pairs SV63
and SV83 (5V-GGTTATGGAGCAGGGGTGG) followed by
SV84 (5V-CACTCAGCTGCTTAAGAGGCTTCACC) and
SV87 (5V-CACATGGACAGGCGCCCTGATCA) using the
Expand Long Template PCR System (Roche).
Purified PCR fragments were subjected to direct
sequencing and additionally cloned into the vector pCR
2.1 TOPO using the TOPO TA Cloning Kit (Invitrogen).
Resulting plasmids were treated with MluI and BclI (NR2,
NR3, NR 4, R2, R3, and R4) or EcoRI and BclI (NR1 andR1) (all enzymes by New England Biolabs). The plasmid
pFK-I389/NS3-3V/ET, containing the sequence of HCV strain
Con-1 with adaptive mutations in NS3 (E1202G and
T1280I) and NS4B (K1846T) (Lohmann et al., 2003), was
restricted by corresponding combinations of endonucleases
and NS5A fragments from AD78 isolates were cloned into
this plasmid with T4 DNA ligase (Fermentas).
Transfection of Huh7 cells, selection of G418-resistant
clones, and Northern blot analysis
Chimeric plasmid constructs were linearized with PvuI
and ScaI (New England Biolabs) and RNA was transcribed
in vitro using the T7 Mega Script Kit (Ambion). Prepared
RNAs were used for transfection of Huh7 cells using
electroporation as described elsewhere (Lohmann et al.,
1999, 2003). G418 at a concentration of 500 Ag/ml was used
for selection of replicon-containing cell clones. G418-
resistant clones were pooled and cell lines harboring
continuous HCV RNA replication were established. Prep-
aration of cellular RNA and Northern blotting was
performed as described earlier (Lohmann et al., 2003).
Treatment with IFN-a and quantitative RT-PCR
Recombinant IFN-a (Sigma) was added to replicon-
containing Huh7 cells to final concentrations of 0.55, 1,67,
5, 15, 45, and 135 U/ml. After 48 h, total cell RNA was
extracted with Trizol (Invitrogen). The number of replicon
Rapid Communication136molecules was determined by real-time RT-PCR using the
LightCycler RNA Amplification Kit Hybridization Probes
(Roche) with the HCV-specific primer pair p47LC (5V-
TGTGAGGAACTACTGTCTTCACGC) and p81LC (5V-
GGTGTACTCACCGGTTCCG). Oligonucleotides hFL
(HCV sensor; 5V-GTGTCGTGCAGCCTCCAGG-Fluores-
cin) and hLC (HCV-anchor; 5V-LC-Red640-CCCCCC-
CTCCCGGGAGAGCC-PH) were used as hybridization
probes. Cycling conditions were as follows: reverse trans-
cription at 55 -C, 30 min; denaturing at 95 -C, 30 s; PCR: 95
-C, 5 s; 52 -C, 15 s; 72 -C, 15 s, 45 cycles; cooling at 40 -C,
30 s. To correct for total RNA amounts in each sample, the
number of mRNA molecules for human glucose-6-phos-
phate dehydrogenase (h-G6PDH) was determined using the
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